TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07714616: Phase III, Multicenter, Open-Label, Single-Arm Clinical Trial to Evaluate the Contraceptive Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-Dose Estrogen in Women of Ch

Sponsor: Eurofarma Laboratorios S.A. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1600 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07714616 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07714616 Rescue Dossier →